Ridazolol
{{Chembox
| ImageFile = ridazolol.svg
| ImageSize = 200px
| ImageAlt =
| IUPACName = 5-Chloro-4-[2-
| OtherNames =
|Section1={{Chembox Identifiers
| CASNo = 83395-21-5
| CASNo_Ref = {{Cascite|changed|CAS}}
| PubChem = 71265
| ChemSpiderID = 64393
| ChEMBL = 1742443
| UNII = 2R4QO1868Y
| InChI = 1/C15H18Cl2N4O3/c16-11-3-1-2-4-13(11)24-9-10(22)7-18-5-6-19-12-8-20-21-15(23)14(12)17/h1-4,8,10,18,22H,5-7,9H2,(H2,19,21,23)
| InChIKey = UUWABVCZFXKHSU-UHFFFAOYAL
| StdInChI = 1S/C15H18Cl2N4O3/c16-11-3-1-2-4-13(11)24-9-10(22)7-18-5-6-19-12-8-20-21-15(23)14(12)17/h1-4,8,10,18,22H,5-7,9H2,(H2,19,21,23)
| StdInChIKey = UUWABVCZFXKHSU-UHFFFAOYSA-N
| SMILES = C1=CC=C(C(=C1)OCC(CNCCNC2=C(C(=O)NN=C2)Cl)O)Cl}}
|Section2={{Chembox Properties
| C=15 | H=18 | Cl=2 | N=4 | O=3
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = }}
}}
Ridazolol is a pharmaceutical drug acting as a beta adrenergic receptor antagonist. It was investigated in the 1980 and 90s for its effects on coronary heart disease and essential hypertension (high blood pressure).{{cite journal|pmid=1353933|year=1992|last1=Fach|first1=WA|last2=Starke|first2=E|last3=Becker|first3=HJ|title=Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease|volume=81|issue=6|pages=320–5|journal=Zeitschrift für Kardiologie}}{{cite journal|doi=10.1007/BF01283029|title=Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension|year=1994|last1=Rommel|first1=Th.|last2=Demisch|first2=L.|journal=Journal of Neural Transmission|volume=95|issue=1|pages=39–48|pmid=7857585|s2cid=31936176}}
It is not known to be marketed anywhere in the world.{{cite web|url=https://www.drugs.com/search.php?searchterm=ridazolol|publisher=Drugs.com|title=Ridazolol search results|accessdate=2021-03-31}}